MedTrace Logo

Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus

NCT00351000 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-01-13

Study results available
· View outcomes & findings →

Summary

This study is a six-week, open label trial of the novel antipsychotic agent, ziprasidone, added to a stable dose of clozapine or olanzapine in 40 diabetes mellitus patients, patients with an impaired fasting glucose or insulin resistance with schizophrenia or schizoaffective disorder. The first two weeks will be a fixed-dose of ziprasidone 40 mg twice a day. During weeks 2-6, the ziprasidone dose may be increased up to 80 mg twice a day.

Conditions

Interventions

DRUG

Ziprasidone

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • North Suffolk Mental Health Association

    lead OTHER

Principal Investigators

  • David C Henderson, MD · North Suffolk Mental Health Association

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00351000 on ClinicalTrials.gov